Covington Represents Elanco in Divestitures of Pet Care Products

WASHINGTON—Covington represented Elanco Animal Health in connection with an agreement with Dechra Pharmaceuticals to divest Osurnia® for $135 million in an all-cash deal. Covington also represented Elanco in an agreement to divest the U.S. rights and related assets for Capstar® to PetIQ, Inc., for $95 million in an all-cash deal.

Elanco is a global animal health company that develops products and knowledge services to prevent and treat disease in animals and pets in more than 90 countries. Osurnia® is a treatment for otitis externa in dogs. Capstar® is an oral tablet that kills fleas in dogs and cats.

The Covington team included Michael Riella, Catherine Dargan, Lauren Visek, and Andrew Barna.